FDA Seeks Feedback on Best Practices for Postmarket Surveillance

The FDA invited comments on a draft guidance that outlines the agency’s best practices for postmarket safety surveillance for drugs and biologics, including product quality issues (PQIs).
Source: Drug GMP Report